{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:50:14Z","timestamp":1740142214083,"version":"3.37.3"},"reference-count":77,"publisher":"Bentham Science Publishers Ltd.","issue":"27","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,8,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Hospitalization rates and survival of patients with Heart Failure (HF) have improved.\nHowever, 5-year mortality rates remain high and the prevalence of the disease is rising likely due to\naging of the population and advances in diagnosis and treatment of other acute and chronic cardiovascular\ndiseases. Over the past three decades the therapeutic armamentarium of heart failure has improved\nsubstantially with development of medications targeting neuro-hormonal activation and devices\npreventing sudden cardiac death and improving cardiac synchrony. Recently, inhibition of angiotensin\nreceptors and neprilysin as well as sinoatrial pacemaker modulating f-current, have been\nfound safe and effective strategies that improve HF hospitalization rates and\/or mortality. Antidiabetic\nagents inhibiting sodium-glucose co-transporters 2, result in natriuresis and osmotic diuresis\nand may further improve HF related outcomes. Furthermore, emerging therapies such as cardiac myosin\nactivators, soluble guanylate cyclase stimulators and non-steroidal mineralocorticoid receptor\nantagonists are undergoing investigation in phase II and III studies of HF patients. Finally, rapid evolution\nof in the management of advanced HF has occurred with the application of second and third\ngeneration continuous flow left ventricular assist devices in clinical practice. Ongoing clinical studies\nwill validate the safety and efficacy of emerging therapeutic strategies in HF population underrepresented\nin previous clinical trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666190523083747","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:09:56Z","timestamp":1558606196000},"page":"4522-4535","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options"],"prefix":"10.2174","volume":"27","author":[{"given":"Alexandros","family":"Briasoulis","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Diseases, Section of Heart Failure and Transplant, University of Iowa Hospitals and Clinics, Iowa City, IA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakradhari","family":"Inampudi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Diseases, Section of Heart Failure and Transplant, University of Iowa Hospitals and Clinics, Iowa City, IA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Hatzis","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Diseases, Section of Heart Failure and Transplant, University of Iowa Hospitals and Clinics, Iowa City, IA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabea","family":"Asleh","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic, Rochester MN, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","volume":"133(4)","author":"Mozaffarian,D.","year":"2016","unstructured":"Mozaffarian,D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman,M.; Das, S.R.; de Ferranti,S.; De-spr\u00e9s, J.P.; Fullerton, H.J.; Howard, V.J.; Huffman, M.D.; Isasi, C.R.; Jim\u00e9nez, M.C.; Judd, S.E.; Kissela, B.M.; Lichtman, J.H.; Lisabeth, L.D.; Liu,S.; Mackey, R.H.; Magid, D.J.; McGuire, D.K.; Mohler, E.R. III.; Moy, C.S.; Muntner,P.; Mussolino, M.E.; Nasir,K.; Neumar, R.W.; Nichol,G.; Palaniappan,L.; Pandey, D.K.; Reeves, M.J.; Rodriguez, C.J.; Rosamond,W.; Sorlie, P.D.; Stein,J.; Tow-fighi,A.; Turan, T.N.; Virani, S.S.; Woo,D.; Yeh, R.W.; Turner, M.B. American Heart Association Statistics Com-mittee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation. 2016,133(4),e38-e360. http:\/\/dx.doi.org\/10.1161\/CIR.0000000000000350 PMID: 26673558","journal-title":"Circulation"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6(3)","author":"Heidenreich, P.A.","year":"2013","unstructured":"Heidenreich, P.A.; Albert, N.M.; Allen, L.A.; Bluemke, D.A.; Butler,J.; Fonarow, G.C.; Ikonomidis, J.S.; Khavjou,O.; Konstam, M.A.; Maddox, T.M.; Nichol,G.; Pham,M.; Pi\u00f1a, I.L.; Trogdon, J.G. American Heart Association Ad-vocacy Coordinating Committee; Council on Arteriosclero-sis, Thrombosis and Vascular Biology; Council on Cardio-vascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American heart association. Circ. Heart Fail. 2013,6(3),606-619. http:\/\/dx.doi.org\/10.1161\/HHF.0b013e318291329a PMID: 23616602","journal-title":"Circ.Heart Fail"},{"author":"Gerber,Y.","key":"ref=3","unstructured":"Gerber,Y.; Weston, S.A.; Redfield, M.M.; Chamberlain, A.M.; Manemann, S.M.; Jiang,R.; Killian, J.M.; Roger, V.L. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota. 2000 to 2010. JAMA Intern. Med. 2015,175(6),996-1004. http:\/\/dx.doi.org\/10.1001\/jamainternmed.2015.0924 PMID: 25895156"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128(16)","author":"Yancy, C.W.","year":"2013","unstructured":"Yancy, C.W.; Jessup,M.; Bozkurt,B.; Butler,J.; Casey, D.E. Jr; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Hor-wich,T.; Januzzi, J.L.; Johnson, M.R.; Kasper, E.K.; Levy, W.C.; Masoudi, F.A.; McBride, P.E.; McMurray, J.J.; Mitchell, J.E.; Peterson, P.N.; Riegel,B.; Sam,F.; Steven-son, L.W.; Tang, W.H.; Tsai, E.J.; Wilkoff, B.L. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American college of car-diology foundation\/American heart association task force on practice guidelines. Circulation. 2013,128(16),1810-1852. http:\/\/dx.doi.org\/10.1161\/CIR.0b013e31829e8807 PMID: 23741057","journal-title":"Circulation"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10741-008-9130-x","volume":"14(4)","author":"Movsesian,M.","year":"2009","unstructured":"Movsesian,M.; Stehlik,J.; Vandeput,F.; Bristow, M.R. Phosphodiesterase inhibition in heart failure. Heart Fail. Rev. 2009,14(4),255-263. http:\/\/dx.doi.org\/10.1007\/s10741-008-9130-x PMID: 19096931","journal-title":"Heart Fail.Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jchf.2017.02.016","volume":"5(7)","author":"Starling, R.C.","year":"2017","unstructured":"Starling, R.C.; Estep, J.D.; Horstmanshof, D.A.; Milano, C.A.; Stehlik,J.; Shah, K.B.; Bruckner, B.A.; Lee,S.; Long, J.W.; Selzman, C.H.; Kasirajan,V.; Haas, D.C.; Boyle, A.J.; Chuang,J.; Farrar, D.J.; Rogers, J.G. ROADMAP Study In-vestigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results,J. ACC Heart Fail. 2017,5(7),518-527. http:\/\/dx.doi.org\/10.1016\/j.jchf.2017.02.016 PMID: 28396040","journal-title":"J.ACC Heart Fail"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15(9)","author":"McMurray, J.J.","year":"2013","unstructured":"McMurray, J.J.; Packer,M.; Desai, A.S.; Gong,J.; Lefkow-itz, M.P.; Rizkala, A.R.; Rouleau,J.; Shi, V.C.; Solomon, S.D.; Swedberg,K.; Zile, M.R. PARADIGM-HF Commit-tees and Investigators. Dual angiotensin receptor and ne-prilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic sys-tolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARA-DIGM-HF) . Eur, J. Heart Fail. 2013,15(9),1062-1073. http:\/\/dx.doi.org\/10.1093\/eurjhf\/hft052 PMID: 23563576","journal-title":"Eur, J.Heart Fail"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1056\/NEJM200007273430403","volume":"343(4)","author":"Colucci, W.S.","year":"2000","unstructured":"Colucci, W.S.; Elkayam,U.; Horton, D.P.; Abraham, W.T.; Bourge, R.C.; Johnson, A.D.; Wagoner, L.E.; Givertz, M.M.; Liang, C.S.; Neibaur,M.; Haught, W.H.; LeJemtel, T.H. Nesiritide Study Group. Intravenous nesiritide, a natri-uretic peptide, in the treatment of decompensated congestive heart failure, N. Engl, J. Med. 2000,343(4),246-253. http:\/\/dx.doi.org\/10.1056\/NEJM200007273430403 PMID: 10911006","journal-title":"N.Engl, J.Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17(2)","author":"Kostis, J.B.","year":"2004","unstructured":"Kostis, J.B.; Packer,M.; Black, H.R.; Schmieder,R.; Henry,D.; Levy, E. Omapatrilat and enalapril in patients with hy-pertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE)  trial. Am, J. Hypertens. 2004,17(2),103-111. http:\/\/dx.doi.org\/10.1016\/j.amjhyper.2003.09.014 PMID: 14751650","journal-title":"enalapril (OCTAVE)  trial.Am, J.Hypertens"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371(11)","author":"McMurray, J.J.","year":"2014","unstructured":"McMurray, J.J.; Packer,M.; Desai, A.S.; Gong,J.; Lefkow-itz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg,K.; Zile, M.R. PARADIGM-HF Investiga-tors and Committees. Angiotensin-neprilysin inhibition ver-sus enalapril in heart failure, N. Engl, J. Med. 2014,371(11),993-1004. http:\/\/dx.doi.org\/10.1056\/NEJMoa1409077 PMID: 25176015","journal-title":"N.Engl, J.Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68(13)","author":"Yancy, C.W.","year":"2016","unstructured":"Yancy, C.W.; Jessup,M.; Bozkurt,B.; Butler,J.; Casey, D.E. Jr; Colvin, M.M.; Drazner, M.H.; Filippatos,G.; Fon-arow, G.C.; Givertz, M.M.; Hollenberg, S.M.; Lindenfeld,J.; Masoudi, F.A.; McBride, P.E.; Peterson, P.N.; Stevenson, L.W.; Westlake, C. 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiol-ogy\/American heart association task force on clinical prac-tice guidelines and the heart failure society of America, J. Am. Coll. Cardiol. 2016,68(13),1476-1488. http:\/\/dx.doi.org\/10.1016\/j.jacc.2016.05.011 PMID: 27216111","journal-title":"J.Am.Coll.Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131(1)","author":"Packer,M.","year":"2015","unstructured":"Packer,M.; McMurray, J.J.; Desai, A.S.; Gong,J.; Lefkow-itz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg,K.; Zile,M.; Andersen,K.; Arango, J.L.; Arnold, J.M.; Belohl\u00e1vek,J.; B\u00f6hm,M.; Boytsov,S.; Bur-gess, L.J.; Cabrera,W.; Calvo,C.; Chen, C.H.; Dukat,A.; Duarte, Y.C.; Erglis,A.; Fu,M.; Gomez,E.; Gonz\u00e0lez-Medina,A.; Hag\u00e8ge, A.A.; Huang,J.; Katova,T.; Kiatchoo-sakun,S.; Kim, K.S.; Kozan, \u00d6.; Llamas, E.B.; Martinez,F.; Merkely,B.; Mendoza,I.; Mosterd,A.; Negrusz-Kawecka,M.; Peuhkurinen,K.; Ramires, F.J.; Refsgaard,J.; Rosen-thal,A.; Senni,M.; Sibulo, A.S. Jr; Silva-Cardoso,J.; Squire, I.B.; Starling, R.C.; Teerlink, J.R.; Vanhaecke,J.; Vinereanu,D.; Wong, R.C. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015,131(1),54-61. http:\/\/dx.doi.org\/ 10.1161\/CIRCULATIONAHA.114.013748 PMID: 25403646","journal-title":"Circulation"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","volume":"36(7)","author":"McMurray,J.","year":"2015","unstructured":"McMurray,J.; Packer,M.; Desai,A.; Gong,J.; Greenlaw,N.; Lefkowitz,M.; Rizkala,A.; Shi,V.; Rouleau,J.; Solo-mon,S.; Swedberg,K.; Zile, M.R.; Andersen,K.; Arango, J.L.; Arnold,M.; Belohl\u00e1vek,J.; B\u00f6hm,M.; Boytsov,S.; Burgess,L.; Cabrera,W.; Chen, C.H.; Erglis,A.; Fu,M.; Gomez,E.; Gonzalez,A.; Hagege, A.A.; Katova,T.; Kiatchoosakun,S.; Kim, K.S.; Bayram,E.; Martinez,F.; Merkely,B.; Mendoza,I.; Mosterd,A.; Negrusz-Kawecka,M.; Peuhkurinen,K.; Ramires,F.; Refsgaard,J.; Senni,M.; Sibulo, A.S. Jr; Silva-Cardoso,J.; Squire,I.; Starling, R.C.; Vinereanu,D.; Teerlink, J.R.; Wong, R. PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart fail-ure. Eur. Heart J. 2015,36(7),434-439. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehu455 PMID: 25416329","journal-title":".Eur.Heart J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJM198409273111303","volume":"311(13)","author":"Cohn, J.N.","year":"1984","unstructured":"Cohn, J.N.; Levine, T.B.; Olivari, M.T.; Garberg,V.; Lura,D.; Francis, G.S.; Simon, A.B.; Rector, T. Plasma norepi-nephrine as a guide to prognosis in patients with chronic congestive heart failure, N. Engl, J. Med. 1984,311(13),819-823. http:\/\/dx.doi.org\/10.1056\/NEJM198409273111303 PMID: 6382011","journal-title":"Engl, J.Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/eurjhf\/hft129","volume":"16(1)","author":"Dobre,D.","year":"2014","unstructured":"Dobre,D.; Borer, J.S.; Fox,K.; Swedberg,K.; Adams, K.F.; Cleland, J.G.; Cohen-Solal,A.; Gheorghiade,M.; Gueyffier,F.; O\u2019Connor, C.M.; Fiuzat,M.; Patak,A.; Pi\u00f1a, I.L.; Ro-sano,G.; Sabbah, H.N.; Tavazzi,L.; Zannad, F. Heart rate: a prognostic factor and therapeutic target in chronic heart fail-ure. The distinct roles of drugs with heart rate-lowering properties. Eur, J. Heart Fail. 2014,16(1),76-85. http:\/\/dx.doi.org\/10.1093\/eurjhf\/hft129 PMID: 23928650","journal-title":"Eur, J.Heart Fail"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10) 61198-1","volume":"376(9744)","author":"Swedberg,K.","year":"2010","unstructured":"Swedberg,K.; Komajda,M.; B\u00f6hm,M.; Borer, J.S.; Ford,I.; Dubost-Brama,A.; Lerebours,G.; Tavazzi, L. SHIFT In-vestigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010,376(9744),875-885. http:\/\/dx.doi.org\/10.1016\/S0140-6736(10) 61198-1 PMID: 20801500","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10) 61259-7","volume":"376(9744)","author":"Bhm,M.","year":"2010","unstructured":"B\u00f6hm,M.; Swedberg,K.; Komajda,M.; Borer, J.S.; Ford,I.; Dubost-Brama,A.; Lerebours,G.; Tavazzi, L. SHIFT In-vestigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010,376(9744),886-894. http:\/\/dx.doi.org\/10.1016\/S0140-6736(10) 61259-7 PMID: 20801495","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","volume":"102(1)","author":"Bhm,M.","year":"2013","unstructured":"B\u00f6hm,M.; Borer,J.; Ford,I.; Gonzalez-Juanatey, J.R.; Ko-majda,M.; Lopez-Sendon,J.; Reil, J.C.; Swedberg,K.; Tavazzi, L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart fail-ure: analysis from the SHIFT study. Clin. Res. Cardiol. 2013,102(1),11-22. http:\/\/dx.doi.org\/10.1007\/s00392-012-0467-8 PMID: 22575988","journal-title":"Clin.Res.Cardiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(10) 61314-1","volume":"376(9744)","author":"Teerlink,J.R","year":"2010","unstructured":"Teerlink.; J.R. Ivabradine in heart failure-no paradigm SHIF yet. Lancet. 2010,376(9744),847-849. http:\/\/dx.doi.org\/10.1016\/S0140-6736(10) 61314-1 PMID: 20801501","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","volume":"100(19)","author":"Martin, R.I.","year":"2014","unstructured":"Martin, R.I.; Pogoryelova,O.; Koref, M.S.; Bourke, J.P.; Teare, M.D.; Keavney, B.D. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised con-trolled trials. Heart. 2014,100(19),1506-1510. http:\/\/dx.doi.org\/10.1136\/heartjnl-2014-305482 PMID: 24951486","journal-title":"Heart"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373(22)","author":"Zinman,B.","year":"2015","unstructured":"Zinman,B.; Wanner,C.; Lachin, J.M.; Fitchett,D.; Bluhmki,E.; Hantel,S.; Mattheus,M.; Devins,T.; Johan-sen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E. EMPA-REG OUTCOME Investigators. Empagliflozin, car-diovascular outcomes, and mortality in type 2 diabetes, N. Engl, J. Med. 2015,373(22),2117-2128. http:\/\/dx.doi.org\/10.1056\/NEJMoa1504720 PMID: 26378978","journal-title":"N.Engl, J.Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377(7)","author":"Neal,B.","year":"2017","unstructured":"Neal,B.; Perkovic,V.; Mahaffey, K.W.; de Zeeuw,D.; Fulcher,G.; Erondu,N.; Shaw,W.; Law,G.; Desai,M.; Matthews, D.R.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes, N. Engl, J. Med. 2017,377(7),644-657. http:\/\/dx.doi.org\/10.1056\/NEJMoa1611925 PMID: 28605608","journal-title":"Engl, J.Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","volume":"39(5)","author":"Fitchett,D.","year":"2018","unstructured":"Fitchett,D.; Butler,J.; van de Borne,P.; Zinman,B.; La-chin, J.M.; Wanner,C.; Woerle, H.J.; Hantel,S.; George, J.T.; Johansen, O.E.; Inzucchi, S.E. EMPA-REG OUT-COME\u00ae trial investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME\u00ae trial. Eur. Heart J. 2018,39(5),363-370. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehx511 PMID: 29020355","journal-title":"Eur.Heart J"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139(11)","author":"Fitchett,D.","year":"2019","unstructured":"Fitchett,D.; Inzucchi, S.E.; Cannon, C.P.; McGuire, D.K.; Scirica, B.M.; Johansen, O.E.; Sambevski,S.; Kaspers,S.; Pfarr,E.; George, J.T.; Zinman, B. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUT-COME trial. Circulation. 2019,139(11),1384-1395. http:\/\/dx.doi.org\/ 10.1161\/CIRCULATIONAHA.118.037778 PMID: 30586757","journal-title":"Circulation"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","volume":"138(17)","author":"Inzucchi, S.E.","year":"2018","unstructured":"Inzucchi, S.E.; Kosiborod,M.; Fitchett,D.; Wanner,C.; Hehnke,U.; Kaspers,S.; George, J.T.; Zinman, B. Im-provement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018,138(17),1904-1907. http:\/\/dx.doi.org\/10. 1161\/CIRCULATIONAHA.118.035759 PMID: 30354665","journal-title":"Circulation"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/eurheartj\/ehr026","volume":"32(15)","author":"Hasenfuss,G.","year":"2011","unstructured":"Hasenfuss,G.; Teerlink, J.R. Cardiac inotropes: current agents and future directions. Eur. Heart J. 2011,32(15),1838-1845. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehr026 PMID: 21388993","journal-title":"Eur.Heart J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","volume":"331(6023)","author":"Malik, F.I.","year":"2011","unstructured":"Malik, F.I.; Hartman, J.J.; Elias, K.A.; Morgan, B.P.; Rodri-guez,H.; Brejc,K.; Anderson, R.L.; Sueoka, S.H.; Lee, K.H.; Finer, J.T.; Sakowicz,R.; Baliga,R.; Cox, D.R.; Ga-rard,M.; Godinez,G.; Kawas,R.; Kraynack,E.; Lenzi,D.; Lu, P.P.; Muci,A.; Niu,C.; Qian,X.; Pierce, D.W.; Pok-rovskii,M.; Suehiro,I.; Sylvester,S.; Tochimoto,T.; Val-dez,C.; Wang,W.; Katori,T.; Kass, D.A.; Shen, Y.T.; Vat-ner, S.F.; Morgans, D.J. Cardiac myosin activation: a poten-tial therapeutic approach for systolic heart failure. Science. 2011,331(6023),1439-1443. http:\/\/dx.doi.org\/10.1126\/science.1200113 PMID: 21415352","journal-title":"Science"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(11) 61219-1","volume":"378(9792)","author":"Teerlink, J.R.","year":"2011","unstructured":"Teerlink, J.R.; Clarke, C.P.; Saikali, K.G.; Lee, J.H.; Chen, M.M.; Escandon, R.D.; Elliott,L.; Bee,R.; Habibzadeh, M.R.; Goldman, J.H.; Schiller, N.B.; Malik, F.I.; Wolff, A.A. Dose-dependent augmentation of cardiac systolic func-tion with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011,378(9792),667-675. http:\/\/dx.doi.org\/10.1016\/S0140-6736(11) 61219-1 PMID: 21856480","journal-title":"Lancet"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(11) 61126-4","volume":"378(9792)","author":"Cleland, J.G.F.","year":"2011","unstructured":"Cleland, J.G.F.; Teerlink, J.R.; Senior,R.; Nifontov, E.M.; Mc Murray, J.J.; Lang, C.C.; Tsyrlin, V.A.; Greenberg, B.H.; Mayet,J.; Francis, D.P.; Shaburishvili,T.; Monaghan,M.; Saltzberg,M.; Neyses,L.; Wasserman, S.M.; Lee, J.H.; Saikali, K.G.; Clarke, C.P.; Goldman, J.H.; Wolff, A.A.; Malik, F.I. The effects of the cardiac myosin activator, ome-camtiv mecarbil, on cardiac function in systolic heart fail-ure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011,378(9792),676-683. http:\/\/dx.doi.org\/10.1016\/S0140-6736(11) 61126-4 PMID: 21856481","journal-title":"Lancet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16) 32049-9","volume":"388(10062)","author":"Teerlink, J.R.","year":"2016","unstructured":"Teerlink, J.R.; Felker, G.M.; McMurray, J.J.; Solomon, S.D.; Adams, K.F. Jr; Cleland, J.G.; Ezekowitz, J.A.; Goudev,A.; Macdonald,P.; Metra,M.; Mitrovic,V.; Ponikowski,P.; Serpytis,P.; Spinar,J.; Tomcs\u00e1nyi,J.; Vandekerckhove, H.J.; Voors, A.A.; Monsalvo, M.L.; Johnston,J.; Malik, F.I.; Honarpour, N. COSMIC-HF Inves-tigators. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lan-cet. 2016,388(10062),2895-2903. http:\/\/dx.doi.org\/10.1016\/S0140-6736(16) 32049-9 PMID: 27914656","journal-title":"Lan-cet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","volume":"67(12)","author":"Teerlink, J.R.","year":"2016","unstructured":"Teerlink, J.R.; Felker, G.M.; McMurray, J.J.V.; Ponikowski,P.; Metra,M.; Filippatos, G.S.; Ezekowitz, J.A.; Dickstein,K.; Cleland, J.G.F.; Kim, J.B.; Lei,L.; Knusel,B.; Wolff, A.A.; Malik, F.I.; Wasserman, S.M. ATOMIC-AHF Inves-tigators. Acute treatment with omecamtiv mecarbil to in-crease contractility in acute heart failure: the ATOMIC-AHF Study, J. Am. Coll. Cardiol. 2016,67(12),1444-1455. http:\/\/dx.doi.org\/10.1016\/j.jacc.2016.01.031 PMID: 27012405","journal-title":"J.Am.Coll.Cardiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e000536","DOI":"10.1161\/JAHA.113.000536","volume":"2(6)","author":"Greene, S.J.","year":"2013","unstructured":"Greene, S.J.; Gheorghiade,M.; Borlaug, B.A.; Pieske,B.; Vaduganathan,M.; Burnett, J.C. Jr; Roessig,L.; Stasch, J.P.; Solomon, S.D.; Paulus, W.J.; Butler, J. The cGMP sig-naling pathway as a therapeutic target in heart failure with preserved ejection fraction, J. Am. Heart Assoc. 2013,2(6),e000536. http:\/\/dx.doi.org\/10.1161\/JAHA.113.000536 PMID: 24334823","journal-title":"J.Am.Heart Assoc"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","volume":"60(16)","author":"Marti, C.N.","year":"2012","unstructured":"Marti, C.N.; Gheorghiade,M.; Kalogeropoulos, A.P.; Geor-giopoulou, V.V.; Quyyumi, A.A.; Butler, J. Endothelial dys-function, arterial stiffness, and heart failure, J. Am. Coll. Cardiol. 2012,60(16),1455-1469. http:\/\/dx.doi.org\/10.1016\/j.jacc.2011.11.082 PMID: 22999723","journal-title":"Am.Coll.Cardiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314(21)","author":"Gheorghiade,M.","year":"2015","unstructured":"Gheorghiade,M.; Greene, S.J.; Butler,J.; Filippatos,G.; Lam, C.S.; Maggioni, A.P.; Ponikowski,P.; Shah, S.J.; Solomon, S.D.; Kraigher-Krainer,E.; Samano, E.T.; M\u00fcller,K.; Roessig,L.; Pieske, B. SOCRATES-REDUCED Inves-tigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial,J. AMA. 2015,314(21),2251-2262. http:\/\/dx.doi.org\/10.1001\/jama.2015.15734 PMID: 26547357","journal-title":"J.AMA"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38(15)","author":"Pieske,B.","year":"2017","unstructured":"Pieske,B.; Maggioni, A.P.; Lam, C.S.P.; Pieske-Kraigher,E.; Filippatos,G.; Butler,J.; Ponikowski,P.; Shah, S.J.; Solomon, S.D.; Scalise, A.V.; Mueller,K.; Roessig,L.; Gheorghiade, M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved ef (SOCRATES-PRESERVED)  study. Eur. Heart J. 2017,38(15),1119-1127. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehw593 PMID: 28369340","journal-title":"Eur.Heart J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ejhf.444","volume":"18(1)","author":"Bramlage,P.","year":"2016","unstructured":"Bramlage,P.; Swift, S.L.; Thoenes,M.; Minguet,J.; Fer-rero,C.; Schmieder, R.E. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur, J. Heart Fail. 2016,18(1),28-37. http:\/\/dx.doi.org\/10.1002\/ejhf.444 PMID: 26634965","journal-title":"Eur, J.Heart Fail"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64(1)","author":"Kolkhof,P.","year":"2014","unstructured":"Kolkhof,P.; Delbeck,M.; Kretschmer,A.; Steinke,W.; Hartmann,E.; B\u00e4rfacker,L.; Eitner,F.; Albrecht-K\u00fcpper,B.; Sch\u00e4fer, S. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat car-diorenal injury, J. Cardiovasc. Pharmacol. 2014,64(1),69-78. http:\/\/dx.doi.org\/10.1097\/FJC.0000000000000091 PMID: 24621652","journal-title":"Cardiovasc.Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34(31)","author":"Pitt,B.","year":"2013","unstructured":"Pitt,B.; Kober,L.; Ponikowski,P.; Gheorghiade,M.; Filip-patos,G.; Krum,H.; Nowack,C.; Kolkhof,P.; Kim, S.Y.; Zannad, F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in pa-tients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 2013,34(31),2453-2463. http:\/\/dx.doi.org\/10.1093\/eurheartj\/eht187 PMID: 23713082","journal-title":"Eur.Heart J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37(27)","author":"Filippatos,G.","year":"2016","unstructured":"Filippatos,G.; Anker, S.D.; B\u00f6hm,M.; Gheorghiade,M.; K\u00f8ber,L.; Krum,H.; Maggioni, A.P.; Ponikowski,P.; Voors, A.A.; Zannad,F.; Kim, S.Y.; Nowack,C.; Palombo,G.; Kolkhof,P.; Kimmeskamp-Kirschbaum,N.; Pieper,A.; Pitt, B. A ra ndomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur. Heart J. 2016,37(27),2105-2114. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehw132 PMID: 27130705","journal-title":"Eur.Heart J"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","volume":"361(23)","author":"Slaughter, M.S.","year":"2009","unstructured":"Slaughter, M.S.; Rogers, J.G.; Milano, C.A.; Russell, S.D.; Conte, J.V.; Feldman,D.; Sun,B.; Tatooles, A.J.; Delgado, R.M. III.; Long, J.W.; Wozniak, T.C.; Ghumman,W.; Far-rar, D.J.; Frazier, O.H. HeartMate II Investigators. Ad-vanced heart failure treated with continuous-flow left ven-tricular assist device, N. Engl, J. Med. 2009,361(23),2241-2251. http:\/\/dx.doi.org\/10.1056\/NEJMoa0909938 PMID: 19920051","journal-title":"HeartMate II Investigators.Ad-vanced heart failure treated with continuous-flow left ven-tricular assist device, N.Engl, J.Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa067758","volume":"357(9)","author":"Miller, L.W.","year":"2007","unstructured":"Miller, L.W.; Pagani, F.D.; Russell, S.D.; John,R.; Boyle, A.J.; Aaronson, K.D.; Conte, J.V.; Naka,Y.; Mancini,D.; Delgado, R.M.; MacGillivray, T.E.; Farrar, D.J.; Frazier, O.H. HeartMate II Clinical Investigators. Use of a continu-ous-flow device in patients awaiting heart transplantation, N. Engl, J. Med. 2007,357(9),885-896. http:\/\/dx.doi.org\/10.1056\/NEJMoa067758 PMID: 17761592","journal-title":"N.Engl, J.Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.jacc.2009.12.052","volume":"55(17)","author":"Rogers, J.G.","year":"2010","unstructured":"Rogers, J.G.; Aaronson, K.D.; Boyle, A.J.; Russell, S.D.; Milano, C.A.; Pagani, F.D.; Edwards, B.S.; Park,S.; John,R.; Conte, J.V.; Farrar, D.J.; Slaughter, M.S. HeartMate II Investigators. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients, J. Am. Coll. Cardiol. 2010,55(17),1826-1834. http:\/\/dx.doi.org\/10.1016\/j.jacc.2009.12.052 PMID: 20413033","journal-title":"J.Am.Coll.Cardiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa1602954","volume":"376(5)","author":"Rogers, J.G.","year":"2017","unstructured":"Rogers, J.G.; Pagani, F.D.; Tatooles, A.J.; Bhat,G.; Slaugh-ter, M.S.; Birks, E.J.; Boyce, S.W.; Najjar, S.S.; Jeevanan-dam,V.; Anderson, A.S.; Gregoric, I.D.; Mallidi,H.; Lead-ley,K.; Aaronson, K.D.; Frazier, O.H.; Milano, C.A. Intrap-ericardial left ventricular assist device for advanced heart failure, N. Engl, J. Med. 2017,376(5),451-460. http:\/\/dx.doi.org\/10.1056\/NEJMoa1602954 PMID: 28146651","journal-title":"Engl, J.Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jacc.2009.03.055","volume":"54(4)","author":"Pagani, F.D.","year":"2009","unstructured":"Pagani, F.D.; Miller, L.W.; Russell, S.D.; Aaronson, K.D.; John,R.; Boyle, A.J.; Conte, J.V.; Bogaev, R.C.; MacGil-livray, T.E.; Naka,Y.; Mancini,D.; Massey, H.T.; Chen,L.; Klodell, C.T.; Aranda, J.M.; Moazami,N.; Ewald, G.A.; Farrar, D.J.; Frazier, O.H. HeartMate II Investigators. Ex-tended mechanical circulatory support with a continuous-flow rotary left ventricular assist device, J. Am. Coll. Car-diol. 2009,54(4),312-321. http:\/\/dx.doi.org\/10.1016\/j.jacc.2009.03.055 PMID: 19608028","journal-title":"J.Am.Coll.Car-diol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCULATIONAHA.109.933960","volume":"123(4)","author":"Birks, E.J.","year":"2011","unstructured":"Birks, E.J.; George, R.S.; Hedger,M.; Bahrami,T.; Wilton,P.; Bowles, C.T.; Webb,C.; Bougard,R.; Amrani,M.; Ya-coub, M.H.; Dreyfus,G.; Khaghani, A. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011,123(4),381-390. http:\/\/dx.doi.org\/ 10.1161\/CIRCULATIONAHA.109.933960 PMID: 21242487","journal-title":"Circulation"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1161\/CIRCULATIONAHA.111.040261","volume":"126(2)","author":"Drakos, S.G.","year":"2012","unstructured":"Drakos, S.G.; Kfoury, A.G.; Stehlik,J.; Selzman, C.H.; Reid, B.B.; Terrovitis, J.V.; Nanas, J.N.; Li, D.Y. Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation. 2012,126(2),230-241. http:\/\/dx.doi.org\/10.1161\/CIRCULATIONAHA.111.040261 PMID: 22777666","journal-title":"Circulation"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.healun.2015.10.003","volume":"34(12)","author":"Kirklin, J.K.","year":"2015","unstructured":"Kirklin, J.K.; Naftel, D.C.; Pagani, F.D.; Kormos, R.L.; Stevenson, L.W.; Blume, E.D.; Myers, S.L.; Miller, M.A.; Baldwin, J.T.; Young, J.B. Seventh INTERMACS annual report: 15,000 patients and counting, J. Heart Lung Trans-plant. 2015,34(12),1495-1504. http:\/\/dx.doi.org\/10.1016\/j.healun.2015.10.003 PMID: 26520247","journal-title":"Heart Lung Trans-plant"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.healun.2008.07.021","volume":"27(10)","author":"Kirklin, J.K.","year":"2008","unstructured":"Kirklin, J.K.; Naftel, D.C.; Stevenson, L.W.; Kormos, R.L.; Pagani, F.D.; Miller, M.A.; Ulisney,K.; Young, J.B. IN-TERMACS database for durable devices for circulatory support: first annual report, J. Heart Lung Transplant. 2008,27(10),1065-1072. http:\/\/dx.doi.org\/10.1016\/j.healun.2008.07.021 PMID: 18926395","journal-title":"Heart Lung Transplant"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1161\/CIRCHEARTFAILURE.108.782599","volume":"1(3)","author":"Kirklin, J.K.","year":"2008","unstructured":"Kirklin, J.K.; Naftel, D.C. Mechanical circulatory support: registering a therapy in evolution. Circ. Heart Fail. 2008,1(3),200-205. http:\/\/dx.doi.org\/10.1161\/CIRCHEARTFAILURE.108.782599 PMID: 19808290","journal-title":"Circ.Heart Fail"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jacc.2007.04.071","volume":"50(8)","author":"Stevenson, L.W.","year":"2007","unstructured":"Stevenson, L.W.; Couper, G. On the fledgling field of me-chanical circulatory support, J. Am. Coll. Cardiol. 2007,50(8),748-751. http:\/\/dx.doi.org\/10.1016\/j.jacc.2007.04.071 PMID: 17707179","journal-title":"Am.Coll.Cardiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/CIRCHEARTFAILURE.111.963991","volume":"5(2)","author":"Park, S.J.","year":"2012","unstructured":"Park, S.J.; Milano, C.A.; Tatooles, A.J.; Rogers, J.G.; Ad-amson, R.M.; Steidley, D.E.; Ewald, G.A.; Sundareswaran, K.S.; Farrar, D.J.; Slaughter, M.S. HeartMate II Clinical In-vestigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ. Heart Fail. 2012,5(2),241-248. http:\/\/dx.doi.org\/10.1161\/CIRCHEARTFAILURE.111.963991 PMID: 22282104","journal-title":"Circ.Heart Fail"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/eurheartj\/ehx036","volume":"40(8)","author":"Mehra,M.R","year":"2019","unstructured":"Mehra.; M.R. The burden of haemocompatibility with left ventricular assist systems: a complex weave. Eur. Heart J. 2019,40(8),673-677. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehx036 PMID: 28329374","journal-title":"Eur.Heart J"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.acvd.2009.03.010","volume":"102(6-7)","author":"Kirsch,M.","year":"2009","unstructured":"Kirsch,M.; Vermes,E.; Damy,T.; Nakashima,K.; S\u00e9n\u00e9-chal,M.; Boval,B.; Drouet,L.; Loisance, D. Single-centre experience with the thoratec paracorporeal ventricular assist device for patients with primary cardiac failure. Arch. Car-diovasc. Dis. 2009,102(6-7),509-518. http:\/\/dx.doi.org\/10.1016\/j.acvd.2009.03.010 PMID: 19664570","journal-title":"Arch.Car-diovasc.Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/00002480-200209000-00018","volume":"48(5)","author":"Wheeldon, D.R.","year":"2002","unstructured":"Wheeldon, D.R.; LaForge, D.H.; Lee,J.; Jansen, P.G.; Jas-sawalla, J.S.; Portner, P.M. Novacor left ventricular assist system long-term performance: comparison of clinical experience with demonstrated in vitro reliability. ASAIO J. 2002,48(5),546-551. http:\/\/dx.doi.org\/10.1097\/00002480-200209000-00018 PMID: 12296577","journal-title":"ASAIO J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMoa012175","volume":"345(20)","author":"Rose, E.A.","year":"2001","unstructured":"Rose, E.A.; Gelijns, A.C.; Moskowitz, A.J.; Heitjan, D.F.; Stevenson, L.W.; Dembitsky,W.; Long, J.W.; Ascheim, D.D.; Tierney, A.R.; Levitan, R.G.; Watson, J.T.; Meier,P.; Ronan, N.S.; Shapiro, P.A.; Lazar, R.M.; Miller, L.W.; Gupta,L.; Frazier, O.H.; Desvigne-Nickens,P.; Oz, M.C.; Poirier, V.L. randomized evaluation of mechanical assis-tance for the treatment of congestive heart Failure (RE-MATCH)  study group. Long-term use of a left ventricular assist device for end-stage heart failure, N. Engl, J. Med. 2001,345(20),1435-1443. http:\/\/dx.doi.org\/10.1056\/NEJMoa012175 PMID: 11794191","journal-title":"N.Engl, J.Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jacc.2007.03.063","volume":"50(8)","author":"Rogers, J.G.","year":"2007","unstructured":"Rogers, J.G.; Butler,J.; Lansman, S.L.; Gass,A.; Portner, P.M.; Pasque, M.K.; Pierson, R.N. III.; Investigators, I.N. INTrEPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial, J. Am. Coll. Cardiol. 2007,50(8),741-747. http:\/\/dx.doi.org\/10.1016\/j.jacc.2007.03.063 PMID: 17707178","journal-title":"J.Am.Coll.Cardiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa040186","volume":"351(9)","author":"Copeland, J.G.","year":"2004","unstructured":"Copeland, J.G.; Smith, R.G.; Arabia, F.A.; Nolan, P.E.; Sethi, G.K.; Tsau, P.H.; McClellan,D.; Slepian, M.J. Car-dioWest Total Artificial Heart Investigators. Cardiac re-placement with a total artificial heart as a bridge to trans-plantation, N. Engl, J. Med. 2004,351(9),859-867. http:\/\/dx.doi.org\/10.1056\/NEJMoa040186 PMID: 15329423","journal-title":"N.Engl, J.Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1161\/CIRCULATIONAHA.111.058412","volume":"125(25)","author":"Aaronson, K.D.","year":"2012","unstructured":"Aaronson, K.D.; Slaughter, M.S.; Miller, L.W.; McGee, E.C.; Cotts, W.G.; Acker, M.A.; Jessup, M.L.; Gregoric, I.D.; Loyalka,P.; Frazier, O.H.; Jeevanandam,V.; Ander-son, A.S.; Kormos, R.L.; Teuteberg, J.J.; Levy, W.C.; Naftel, D.C.; Bittman, R.M.; Pagani, F.D.; Hathaway, D.R.; Boyce, S.W. HeartWare Ventricular Assist Device (HVAD)  Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in pa-tients awaiting heart transplantation. Circulation. 2012,125(25),3191-3200. http:\/\/dx.doi.org\/ 10.1161\/CIRCULATIONAHA.111.058412 PMID: 22619284","journal-title":"Circulation"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.jacc.2014.01.053","volume":"63(17)","author":"Jorde, U.P.","year":"2014","unstructured":"Jorde, U.P.; Kushwaha, S.S.; Tatooles, A.J.; Naka,Y.; Bhat,G.; Long, J.W.; Horstmanshof, D.A.; Kormos, R.L.; Teute-berg, J.J.; Slaughter, M.S.; Birks, E.J.; Farrar, D.J.; Park, S.J. HeartMate II Clinical Investigators. Results of the des-tination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Inter-agency Registry for Mechanically Assisted Circulatory Sup-port) . J. Am. Coll. Cardiol. 2014,63(17),1751-1757. http:\/\/dx.doi.org\/10.1016\/j.jacc.2014.01.053 PMID: 24613333","journal-title":"Results of the des-tination therapy post-food and drug administration approval study withacontinuous flow left ventricular assist device:aprospective study using the INTERMACSregistry (Inter-agency Registry for Mechanically Assisted Circulatory Sup-port) .J.Am.Coll.Cardiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1610426","volume":"376(5)","author":"Mehra, M.R.","year":"2017","unstructured":"Mehra, M.R.; Naka,Y.; Uriel,N.; Goldstein, D.J.; Cleve-land, J.C. Jr; Colombo, P.C.; Walsh, M.N.; Milano, C.A.; Patel, C.B.; Jorde, U.P.; Pagani, F.D.; Aaronson, K.D.; Dean, D.A.; McCants,K.; Itoh,A.; Ewald, G.A.; Horstman-shof,D.; Long, J.W.; Salerno,C.; Investigators, M. MO-MENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure, N. Engl, J. Med. 2017,376(5),440-450. http:\/\/dx.doi.org\/10.1056\/NEJMoa1610426 PMID: 27959709","journal-title":"N.Engl, J.Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2015.07.075","volume":"66(16)","author":"Estep, J.D.","year":"2015","unstructured":"Estep, J.D.; Starling, R.C.; Horstmanshof, D.A.; Milano, C.A.; Selzman, C.H.; Shah, K.B.; Loebe,M.; Moazami,N.; Long, J.W.; Stehlik,J.; Kasirajan,V.; Haas, D.C.; O\u2019Connell, J.B.; Boyle, A.J.; Farrar, D.J.; Rogers, J.G.; In-vestigators, R.S. ROADMAP Study Investigators. Risk as-sessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study, J. Am. Coll. Cardiol. 2015,66(16),1747-1761. http:\/\/dx.doi.org\/10.1016\/j.jacc.2015.07.075 PMID: 26483097","journal-title":"J.Am.Coll.Cardiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.healun.2017.12.003","volume":"37(6)","author":"Shah, K.B.","year":"2018","unstructured":"Shah, K.B.; Starling, R.C.; Rogers, J.G.; Horstmanshof, D.A.; Long, J.W.; Kasirajan,V.; Stehlik,J.; Chuang,J.; Far-rar, D.J.; Estep, J.D. ROADMAP Investigators. Left ven-tricular assist devices versus medical management in ambu-latory heart failure patients: an analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study, J. Heart Lung Transplant. 2018,37(6),706-714. http:\/\/dx.doi.org\/10.1016\/j.healun.2017.12.003 PMID: 29275844","journal-title":"Left ven-tricular assist devices versus medical management in ambu-latory heart failure patients: an analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAPstudy, J.Heart Lung Transplant"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367(14)","author":"Thiele,H.","year":"2012","unstructured":"Thiele,H.; Zeymer,U.; Neumann, F.J.; Ferenc,M.; Olbrich, H.G.; Hausleiter,J.; Richardt,G.; Hennersdorf,M.; Empen,K.; Fuernau,G.; Desch,S.; Eitel,I.; Hambrecht,R.; Fuhr-mann,J.; B\u00f6hm,M.; Ebelt,H.; Schneider,S.; Schuler,G.; Werdan, K. IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock, N. Engl, J. Med. 2012,367(14),1287-1296. http:\/\/dx.doi.org\/10.1056\/NEJMoa1208410 PMID: 22920912","journal-title":"N.Engl, J.Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(13) 61783-3","volume":"382(9905)","author":"Thiele,H.","year":"2013","unstructured":"Thiele,H.; Zeymer,U.; Neumann, F.J.; Ferenc,M.; Olbrich, H.G.; Hausleiter,J.; de Waha,A.; Richardt,G.; Henners-dorf,M.; Empen,K.; Fuernau,G.; Desch,S.; Eitel,I.; Ham-brecht,R.; Lauer,B.; B\u00f6hm,M.; Ebelt,H.; Schneider,S.; Werdan,K.; Schuler, G. Intraaortic Balloon Pump in car-diogenic shock II (IABP-SHOCK II)  trial investigators. In-tra-aortic balloon counterpulsation in acute myocardial in-farction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013,382(9905),1638-1645. http:\/\/dx.doi.org\/10.1016\/S0140-6736(13) 61783-3 PMID: 24011548","journal-title":"Lancet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"CD007398","DOI":"10.1002\/14651858.CD007398.pub3","volume":"27(3)","author":"Unverzagt,S.","year":"2015","unstructured":"Unverzagt,S.; Buerke,M.; de Waha,A.; Haerting,J.; Pietzner,D.; Seyfarth,M.; Thiele,H.; Werdan,K.; Zeymer,U.; Prondzinsky, R. Intra-aortic balloon pump counterpulsa-tion (IABP)  for myocardial infarction complicated by car-diogenic shock. Cochrane Database Syst. Rev. 2015,27(3),CD007398. http:\/\/dx.doi.org\/10.1002\/14651858.CD007398.pub3 PMID: 25812932","journal-title":"Cochrane Database Syst.Rev"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.jacc.2008.05.065","volume":"52(19)","author":"Seyfarth,M.","year":"2008","unstructured":"Seyfarth,M.; Sibbing,D.; Bauer,I.; Fr\u00f6hlich,G.; Bott-Fl\u00fcgel,L.; Byrne,R.; Dirschinger,J.; Kastrati,A.; Sch\u00f6mig, A. A randomized clinical trial to evaluate the safety and ef-ficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction, J. Am. Coll. Car-diol. 2008,52(19),1584-1588. http:\/\/dx.doi.org\/10.1016\/j.jacc.2008.05.065 PMID: 19007597","journal-title":"Am.Coll.Car-diol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jacc.2016.10.022","volume":"69","author":"Ouweneel, D.M.","year":"2017","unstructured":"Ouweneel, D.M.; Eriksen,E.; Sjauw, K.D.; van Dongen, I.M.; Hirsch,A.; Packer, E.J.; Vis,M.; Wykrzykowska, J.J.; Koch, K.T.; Baan,J.; de Winter, R.J.; Piek, J.J.; Lagrand, W.L.; de Mol, B.A.; Tijssen, J.G.; Henriques, J.P. Impella CP versus intra-aortic balloon pump support in acute myo-cardial infarction complicated by cardiogenic shock. The IMPRESS in severe shock trial, J. Am. Coll. Cardiol. 2017,69,278-287. http:\/\/dx.doi.org\/10.1016\/j.jacc.2016.10.022 PMID: 27810347","journal-title":"J.Am.Coll.Cardiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.112.098194","volume":"126(14)","author":"O \u0099Neill, W.W.","year":"2012","unstructured":"O\u2019Neill, W.W.; Kleiman, N.S.; Moses,J.; Henriques, J.P.; Dixon,S.; Massaro,J.; Palacios,I.; Maini,B.; Mulukutla,S.; Dzav\u00edk,V.; Popma,J.; Douglas, P.S.; Ohman, M. A pro-spective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012,126(14),1717-1727. http:\/\/dx.doi.org\/ 10.1161\/CIRCULATIONAHA.112.098194 PMID: 22935569","journal-title":"Circulation"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1093\/eurheartj\/ehx363","volume":"38(47)","author":"Thiele,H.","year":"2017","unstructured":"Thiele,H.; Jobs,A.; Ouweneel, D.M.; Henriques, J.P.S.; Seyfarth,M.; Desch,S.; Eitel,I.; P\u00f6ss,J.; Fuernau,G.; de Waha, S. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and col-laborative meta-analysis of randomized trials. Eur. Heart J. 2017,38(47),3523-3531. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehx363 PMID: 29020341","journal-title":"Eur.Heart J"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/MAT.0000000000000475","volume":"63(1)","author":"Thiagarajan, R.R.","year":"2017","unstructured":"Thiagarajan, R.R.; Barbaro, R.P.; Rycus, P.T.; Mcmullan, D.M.; Conrad, S.A.; Fortenberry, J.D.; Paden, M.L. ELSO member centers. Extracorporeal life support organization registry international report 2016. ASAIO J. 2017,63(1),60-67. http:\/\/dx.doi.org\/10.1097\/MAT.0000000000000475 PMID: 27984321","journal-title":"ASAIO J"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.athoracsur.2015.07.046","volume":"101(2)","author":"Mazzeffi,M.","year":"2016","unstructured":"Mazzeffi,M.; Greenwood,J.; Tanaka,K.; Menaker,J.; Rec-tor,R.; Herr,D.; Kon,Z.; Lee,J.; Griffith,B.; Rajagopal,K.; Pham, S. Bleeding, transfusion, and mortality on extra-corporeal life support: ECLS working group on thrombosis and hemostasis. Ann. Thorac. Surg. 2016,101(2),682-689. http:\/\/dx.doi.org\/10.1016\/j.athoracsur.2015.07.046 PMID: 26443879","journal-title":"Ann.Thorac.Surg"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.healun.2010.01.011","volume":"29(4) (Suppl.)","author":"Slaughter, M.S.","year":"2010","unstructured":"Slaughter, M.S.; Pagani, F.D.; Rogers, J.G.; Miller, L.W.; Sun,B.; Russell, S.D.; Starling, R.C.; Chen,L.; Boyle, A.J.; Chillcott,S.; Adamson, R.M.; Blood, M.S.; Camacho, M.T.; Idrissi, K.A.; Petty,M.; Sobieski,M.; Wright,S.; Myers, T.J.; Farrar, D.J. HeartMate II Clinical Investigators. Clini-cal management of continuous-flow left ventricular assist devices in advanced heart failure, J. Heart Lung Trans-plant. 2010,29(4) (Suppl.),S1-S39. http:\/\/dx.doi.org\/10.1016\/j.healun.2010.01.011 PMID: 20181499","journal-title":"J.Heart Lung Trans-plant"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.healun.2018.08.001","volume":"37(12)","author":"Anderson,M.","year":"2018","unstructured":"Anderson,M.; Morris, D.L.; Tang,D.; Batsides,G.; Kirtane,A.; Hanson,I.; Meraj,P.; Kapur, N.K.; O\u2019Neill, W. Out-comes of patients with right ventricular failure requiring short-term hemodynamic support with the Impella RP de-vice, J. Heart Lung Transplant. 2018,37(12),1448-1458. http:\/\/dx.doi.org\/10.1016\/j.healun.2018.08.001 PMID: 30241890","journal-title":"Heart Lung Transplant"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ccd.26348","volume":"88(3)","author":"Aggarwal,V.","year":"2016","unstructured":"Aggarwal,V.; Einhorn, B.N.; Cohen, H.A. Current status of percutaneous right ventricular assist devices: first-in-man use of a novel dual lumen cannula. Catheter. Cardiovasc. Interv. 2016,88(3),390-396. http:\/\/dx.doi.org\/10.1002\/ccd.26348 PMID: 26895620","journal-title":"Catheter.Cardiovasc.Interv"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"183","DOI":"10.12659\/MSMBR.895418","volume":"21","author":"Samak,M.","year":"2015","unstructured":"Samak,M.; Fatullayev,J.; Sabashnikov,A.; Zeriouh,M.; Rahmanian, P.B.; Choi, Y.H.; Wippermann,J.; Wahlers,T.; Schmack,B.; Ruhparwar,A.; Dohmen, P.M.; Karck,M.; Popov, A.F.; Simon, A.R.; Weymann, A. Past and present of total artificial heart therapy: a success story. Med. Sci. Monit. Basic Res. 2015,21,183-190. http:\/\/dx.doi.org\/10.12659\/MSMBR.895418 PMID: 26343363","journal-title":"Med.Sci.Monit.Basic Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.transproceed.2013.02.073","volume":"45(3)","author":"Ozbaran,M.","year":"2013","unstructured":"Ozbaran,M.; Yagdi,T.; Engin,C.; Erkul,S.; Balcioglu,O.; Baysal,B.; Nalbantgil,S.; Ertugay, S. Long-term paracorpo-real ventricular support systems: a single-center experience. Transplant. Proc. 2013,45(3),1013-1016. http:\/\/dx.doi.org\/10.1016\/j.transproceed.2013.02.073 PMID: 23622611","journal-title":"Transplant.Proc"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1161\/CIRCULATIONAHA.110.011502","volume":"124(11) (Suppl.)","author":"Krabatsch,T.","year":"2011","unstructured":"Krabatsch,T.; Potapov,E.; Stepanenko,A.; Schweiger,M.; Kukucka,M.; Huebler,M.; Hennig,E.; Hetzer, R. Biven-tricular circulatory support with two miniaturized implant-able assist devices. Circulation. 2011,124(11) (Suppl.),S179-S186. http:\/\/dx.doi.org\/ 10.1161\/CIRCULATIONAHA.110.011502 PMID: 21911810","journal-title":"Circulation"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/172244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T15:08:51Z","timestamp":1605193731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/172244\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":77,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2020,8,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190523083747","relation":{},"ISSN":["0929-8673"],"issn-type":[{"type":"print","value":"0929-8673"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}